Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Authors
Keywords
Ovarian Carcinoma, Trabectedin, Checkpoint Inhibitor, Tumor Protection, Peritoneal Lavage Fluid
Journal
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-07-28
DOI
10.1186/s12967-015-0613-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells
- (2015) Hyangsoon Noh et al. Cell Communication and Signaling
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
- (2015) Christina Wefers et al. GYNECOLOGIC ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint modulation: Rational design of combination strategies
- (2015) Dmitriy Zamarin et al. PHARMACOLOGY & THERAPEUTICS
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Checkpoint inhibitors in immunotherapy of ovarian cancer
- (2014) Dong-hui Wang et al. TUMOR BIOLOGY
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- CD4 CTL: Living up to the challenge
- (2013) Hilde Cheroutre et al. SEMINARS IN IMMUNOLOGY
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
- (2012) Renee Vermeij et al. CURRENT PHARMACEUTICAL DESIGN
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
- (2012) Bradley J. Monk et al. EUROPEAN JOURNAL OF CANCER
- Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma
- (2012) Huafeng Wei et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Immunotherapy in ovarian cancer
- (2012) Gina M. Mantia-Smaldone et al. Human Vaccines & Immunotherapeutics
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for Ovarian Cancer: What's Next?
- (2010) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started